Dolutegravir: first global approval (Q38139885)

29 August 2017

Dolutegravir: first global approval (English)

1 reference

29 August 2017

1 reference

ChEBI release 2020-05-28

2

Caroline M Perry

1 reference

29 August 2017

Anita D Ballantyne

1

1 reference

29 August 2017

1 September 2013

1 reference

29 August 2017

1 reference

29 August 2017

73

1 reference

29 August 2017

14

1 reference

29 August 2017

1627-1637

1 reference

https://scigraph.springernature.com/pub.10.1007/s40265-013-0121-4

29 August 2017

0 references

cites work

Clinical use of HIV integrase inhibitors: a systematic review and meta-analysis

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0121-4

Resistance to HIV integrase inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0121-4

Impact of primary elvitegravir resistance-associated mutations in HIV-1 integrase on drug susceptibility and viral replication fitness

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0121-4

Integrase inhibitors in the treatment of HIV-1 infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0121-4

Safety and efficacy of dolutegravir in treatment-experienced subjects with raltegravir-resistant HIV type 1 infection: 24-week results of the VIKING Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0121-4

The development of novel HIV integrase inhibitors and the problem of drug resistance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0121-4

HIV-1 antiretroviral resistance: scientific principles and clinical applications

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0121-4

Emerging patterns and implications of HIV-1 integrase inhibitor resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0121-4

S/GSK1349572, a new integrase inhibitor for the treatment of HIV: promises and challenges

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0121-4

Next-generation integrase inhibitors : where to after raltegravir?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0121-4

The activity of the integrase inhibitor dolutegravir against HIV-1 variants isolated from raltegravir-treated adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0121-4

Prevalent polymorphisms in wild-type HIV-1 integrase are unlikely to engender drug resistance to dolutegravir (S/GSK1349572).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0121-4

Dolutegravir in antiretroviral-naive adults with HIV-1: 96-week results from a randomized dose-ranging study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0121-4

Pharmacokinetics and safety of S/GSK1349572, a next-generation HIV integrase inhibitor, in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0121-4

Effect of food on the pharmacokinetics of the integrase inhibitor dolutegravir

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0121-4

Metabolism, excretion, and mass balance of the HIV-1 integrase inhibitor dolutegravir in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0121-4

In vitro investigations into the roles of drug transporters and metabolizing enzymes in the disposition and drug interactions of dolutegravir, a HIV integrase inhibitor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0121-4

The effect of lopinavir/ritonavir and darunavir/ritonavir on the HIV integrase inhibitor S/GSK1349572 in healthy participants.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0121-4

Effects of etravirine alone and with ritonavir-boosted protease inhibitors on the pharmacokinetics of dolutegravir

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0121-4

Effect of atazanavir and atazanavir/ritonavir on the pharmacokinetics of the next-generation HIV integrase inhibitor, S/GSK1349572.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0121-4

Lack of interaction between the HIV integrase inhibitor S/GSK1349572 and tenofovir in healthy subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0121-4

Once-daily dolutegravir versus raltegravir in antiretroviral-naive adults with HIV-1 infection: 48 week results from the randomised, double-blind, non-inferiority SPRING-2 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0121-4

Dolutegravir versus raltegravir in antiretroviral-experienced, integrase-inhibitor-naive adults with HIV: week 48 results from the randomised, double-blind, non-inferiority SAILING study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0121-4

Antiviral activity, safety, and pharmacokinetics/pharmacodynamics of dolutegravir as 10-day monotherapy in HIV-1-infected adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0121-4

Effect of a single supratherapeutic dose of dolutegravir on cardiac repolarization

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0121-4

Once daily dolutegravir (S/GSK1349572) in combination therapy in antiretroviral-naive adults with HIV: planned interim 48 week results from SPRING-1, a dose-ranging, randomised, phase 2b trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0121-4

Safety, tolerability, and pharmacokinetics of the HIV integrase inhibitor dolutegravir given twice daily with rifampin or once daily with rifabutin: results of a phase 1 study among healthy subjects

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/24052331

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

British HIV Association guidelines for the treatment of HIV-1-positive adults with antiretroviral therapy 2012.

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/24052331

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Pharmacokinetics of the HIV integrase inhibitor S/GSK1349572 co-administered with acid-reducing agents and multivitamins in healthy volunteers

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/24052331

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1007/S40265-013-0121-4

1 reference

PubMed ID

24052331

Dimensions Publication ID

29 August 2017

0 references

1 reference

PubMed ID

24052331